$21.00
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Composition:


active ingredients: 1 tablet contains: antibodies to human interferon gamma affinity purified: a mixture of homeopathic dilutions C12, C30 and C50 - 6 mg; antibodies to histamine affinity purified: a mixture of homeopathic dilutions C12, C30 and C50 - 6 mg; antibodies to CD4 affinity purified: a mixture of homeopathic dilutions C12, C30 and C50 – 6 mg;


excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.


Dosage form. Pills.


Basic physical and chemical properties: tablets are flat-cylindrical in shape, with a risk and chamfer, from white to almost white in color.


One flat side is marked with a dash, and the other flat side is marked with the inscription ERGOFERON.


Pharmacotherapeutic group. Homeopathic medicine.


Pharmacological properties.


Antiviral agent,antihistamine.


The spectrum of pharmacological activity of the drug includes antiviral, immunomodulatory, antihistamine, anti-inflammatory effects.


The effectiveness of using the components of the drug in the treatment of such viral infectious diseases as influenza A and influenza B, acute respiratory viral infections (caused by parainfluenza viruses, adenoviruses, respiratory syncytial viruses, coronaviruses), herpesvirus infections (labial herpes, ophthalmoherpes, genital herpes, herpes zoster, chickenpox, infectious mononucleosis), acute intestinal infections of viral etiology (caused by caliciviruses, coronaviruses, rotaviruses, enteroviruses), enterovirus and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis.


The drug is used as part of the complex therapy of bacterial infections [pseudotuberculosis, whooping cough, yersiniosis, pneumonia of various etiologies, including atypical pathogens (M. pneumoniae, C. pneumoniae, Legionella spp.)], for the Prevention of bacterial complications of viral infections, superinfections. The use of the drug in the pre - and post-vaccination period increases the effectiveness of vaccination, provides non-specific prevention of acute respiratory viral infections and influenza at the time of formation of post-vaccination immunity. The drug has preventive effectiveness against acute respiratory viral infections of non-influenza etiology, prevents the development of intercurrent diseases in the post-vaccination period.


The components that make up the drug have a single mechanism of action in the form of an increase in the functional activity of the CD4 receptor, interferon gamma (IFN-γ) and histamine receptors, respectively, which is accompanied by a pronounced immunotropic effect.


It has been experimentally proven that: antibodies to interferon gamma increase the expression of IFN-γ, IFN-α/β and related interleukins (IL-2, IL-4, IL-10, etc.), improve the ligand-receptor interaction of IFN, restore cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-γ, which is an important factor in the body's natural antiviral tolerance; they stimulate interferon-dependent biological processes: induction of expression of antigens of the main histocompatibility complex of types I, II and Fc receptors, activation of monocytes, stimulation of functional activity of NK cells, regulation of immunoglobulin synthesis, activating a mixed Th1 and Th2 immune response.


Antibodies to CD4, presumably being allosteric modulators of this receptor, regulate the functional activity of the CD4 receptor, which leads to an increase in the functional activity of CD4 lymphocytes, normalization of the CD4/CD8 immunoregulatory index, as well as the subpopulation composition of immunocompetent cells (CD3, CD4, CD8, CD16, CD20).


Antibodies to histamine modify histamine-dependent activation of peripheral and central H1 receptors and thus reduce bronchial smooth muscle tone, reduce capillary permeability, which leads to a reduction in the duration and severity of rhinorrhea, swelling of the nasal mucosa, coughing and sneezing, as well as a decrease in the severity of allergic reactions associated with the infectious process by inhibiting the release of histamine from mast cells and basophils, the production of leukotrienes, the synthesis of adhesion molecules, reduced eosinophil chemotaxis and platelet aggregation in allergen contact reactions.


The combined use of the components that make up the complex drug is accompanied by an increase in their antiviral activity.


Clinical characteristics.


Indications.


Prevention and treatment:


- flu A and B;


- acute respiratory viral infections caused by parainfluenza virus, adenovirus, respiratory syncytial virus, coronavirus;


- herpesvirus infections (labial herpes, ophthalmic herpes, genital herpes, chickenpox, herpes zoster, infectious mononucleosis);


- acute intestinal infections of viral etiology (caused by calicivirus, adenovirus, coronavirus, rotavirus, enteroviruses);


- enterovirus and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis.


Use in the complex therapy of bacterial infections [pseudotuberculosis, whooping cough, yersiniosis, pneumonia of various etiologies, including those caused by atypical pathogens (M. pneumoniae, C. pneumoniae, Legionella spp.)]; prevention of bacterial complications of viral infections, superinfections.


Contraindications.


Increased individual sensitivity to the components of the drug.


Interactions with other drugs and other types of interactions.


No cases of interaction with other drugs were detected.


Application features.


The drug contains lactose, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, and with congenital lactase deficiency.


Use during pregnancy or lactation.


There are no data on the efficacy and safety of the drug in pregnant or breast-feeding women, so it should not be prescribed to such patients.


Ability to influence the reaction rate when driving vehicles or other mechanisms.


The drug does not affect the ability to drive vehicles and other potentially dangerous mechanisms.


Dosage and administration.


Apply to adults and children aged from 6 months. The drug is taken orally, 1 tablet at a time (do not use the drug with food). The tablet is kept in the mouth (preferably without chewing or swallowing) until completely dissolved.


Children from 6 months of age. If the drug is prescribed to young children (from 6 months to 3 years), it is recommended to dissolve the tablet in a small amount (1 tablespoon) of boiled water at room temperature.


Treatment should be started as early as possible when the first signs of acute viral infection appear according to the following scheme: for the first 2 hours, the drug is taken every 30 minutes, then during the first day – 3 more tablets at regular intervals. Starting from the 2nd day and in the future, the drug is taken 1 tablet 3 times a day until complete recovery.


For the Prevention of viral infectious diseases – 1-2 tablets per day. The recommended duration of the preventive course is determined individually and can be 1-6 months.


If necessary, the drug can be combined with other antiviral and symptomatic agents.


Children.


The drug is used for children aged from 6 months.


Overdose.


In case of accidental overdose, dyspeptic manifestations may occur due to the fillers that make up the drug.


Adverse reactions.


Possible reactions of increased individual sensitivity to the components of the drug.

Tags: Ergoferon